Ladenburg Thalmann Upgrades Intra-Cellular Therapies (ITCI) to Buy

August 30, 2017 7:38 AM EDT
Get Alerts ITCI Hot Sheet
Price: $37.76 +2.75%

Rating Summary:
    16 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 9 | Down: 10 | New: 35
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Ladenburg Thalmann upgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Neutral to Buy with a price target of $36.00.

Analyst Chris James is positive on the company following positive FDA update on Schizophrenia program. The analyst comments "With over 1,500 people exposed to date, lumateperone's prolife is well-tolerated with a safety profile similar to that of placebo. Given the safety and tolerability limitations of existing antipsychotics (e.g., cardiovascular abnormalities, metabolic dysregulation and motor disturbances), we believe lumateperone will be an attractive treatment option for patients with schizophrenia."

For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.

Shares of Intra-Cellular Therapies closed at $15.90 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Upgrades, Upgrades

Related Entities

The Children's Investment Fund (TCI), Ladenburg Thalmann Financial Services, FDA